Introduction & Objective: TZP is a once weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) approved in the US for treatment of T2D and obesity. The goal of this single-cohort retrospective study was to assess effectiveness of TZP in patients (pts) with T2D in a US commercially insured population.
Methods: Adult pts diagnosed with T2D, initiating TZP between 5/2022 and 8/2023, with ≥1 A1C result around initiation and another 6 months post-initiation were identified from the Healthcare Integrated Research Database (HIRD®). Baseline demographics, A1C and weight outcomes at 6-month follow-up for overall cohort and stratified by prior GLP-1 RA use and baseline A1C (<7% vs ≥7%) were described.
Results: Among 2,247 identified pts: mean age 54 years, 58% female, 46% no prior GLP-1 RA use, 59% A1C ≥7%, 61% had overweight/obesity. At 6-month follow up, mean pre-post change in A1C was -1.0% in the overall cohort, -1.4% among pts with baseline A1C ≥7%, and -1.3% in those without prior GLP-1 RA use. Mean change in weight was -6.3 kgs for overall cohort, -5.8 kgs in pts with baseline A1C ≥7%, and -8.1 kgs in those without prior GLP-1 RA use. Further outcomes are summarized in Table 1.
Conclusion: At 6-month follow up, pts initiating TZP in the real world showed reductions in A1C and weight, with greater A1C decreases observed among pts with no prior GLP-1 RA use or with baseline A1C ≥7%.
R. Mody: Employee; Eli Lilly and Company. K. Desai: Employee; Carelon Research. Stock/Shareholder; Anthem, Inc. C. Teng: Employee; Carelon Research. G. Reznor: None. G. Stockbower: None. M. Grabner: Employee; Carelon Research. Stock/Shareholder; Anthem, Inc. B.D. Benneyworth: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.
